Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Drug company (FDA labeler)

Breckenridge Pharmaceutical, Inc.

NDC labeler code: 51991

What is a labeler?

The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.

Official FDA data only

Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.

Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.

At a glance

75Products (NDC)

Prescription medicines

FDA applications for these products

  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
ApprovedApplicationMedicineSponsor
June 3, 2026ANDA209633 Tofacitinib
TOFACITINIB CITRATE
Breckenridge
June 23, 2025ANDA219444 Alcohol
DEHYDRATED ALCOHOL
Breckenridge
January 28, 2025ANDA217640 Everolimus
EVEROLIMUS
Natco
December 16, 2024ANDA218252 Methadone hydrochloride
METHADONE HYDROCHLORIDE
Breckenridge
March 17, 2022ANDA204921 Lacosamide
LACOSAMIDE
Msn Labs Pvt Ltd
August 23, 2021ANDA215409 Penicillamine
PENICILLAMINE
Breckenridge
May 20, 2021ANDA205432 Everolimus
EVEROLIMUS
Breckenridge
March 5, 2021ANDA205426 Everolimus
EVEROLIMUS
Breckenridge
January 22, 2021ANDA214455 Norepinephrine bitartrate
NOREPINEPHRINE BITARTRATE
Breckenridge
December 10, 2020ANDA205960 Asenapine
ASENAPINE MALEATE
Breckenridge
October 30, 2020ANDA210111 Pomalidomide
POMALIDOMIDE
Breckenridge
June 4, 2020ANDA213592 Zolpidem tartrate
ZOLPIDEM TARTRATE
Breckenridge
November 26, 2019ANDA209063 Rivastigmine
RIVASTIGMINE
Breckenridge
February 21, 2019ANDA211031 Exemestane
EXEMESTANE
Breckenridge
November 7, 2018ANDA210662 Tetracycline hydrochloride
TETRACYCLINE HYDROCHLORIDE
Breckenridge
September 14, 2018ANDA208283 Eplerenone
EPLERENONE
Breckenridge
April 15, 2016ANDA208127 Trimipramine maleate
TRIMIPRAMINE MALEATE
Breckenridge
January 27, 2016ANDA205071 Milnacipran hydrochloride
MILNACIPRAN HYDROCHLORIDE
Breckenridge
June 29, 2015ANDA204003 Desvenlafaxine
DESVENLAFAXINE SUCCINATE
Alembic
June 11, 2014ANDA203088 Duloxetine
DULOXETINE HYDROCHLORIDE
Breckenridge
December 6, 2011ANDA040642 Methscopolamine bromide
METHSCOPOLAMINE BROMIDE
Breckenridge Pharm
July 15, 2011ANDA078703 Propranolol hydrochloride
PROPRANOLOL HYDROCHLORIDE
Adare Pharms Inc
June 3, 2011ANDA200161 Letrozole
LETROZOLE
Natco Pharma Ltd
September 13, 2010ANDA040889 Methylergonovine maleate
METHYLERGONOVINE MALEATE
Breckenridge
June 28, 2010ANDA079220 Anastrozole
ANASTROZOLE
Natco Pharma Ltd
Show the other 6 applications
ApprovedApplicationMedicineSponsor
June 4, 2010ANDA077714 Terbinafine hydrochloride
TERBINAFINE HYDROCHLORIDE
Breckenridge Pharm
June 22, 2009ANDA078969 Granisetron
GRANISETRON HYDROCHLORIDE
Natco Pharma
April 17, 2008ANDA078324 Estradiol and norethindrone acetate
ESTRADIOL AND NORETHINDRONE ACETATE
Breckenridge Pharm
January 11, 2008ANDA078069 Oxcarbazepine
OXCARBAZEPINE
Breckenridge Pharm
June 10, 2004ANDA076560 Butalbital, acetaminophen, caffeine and codeine phosphate
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE
Lgm Pharma
November 30, 2001ANDA075231 Butalbital, aspirin, caffeine and codeine phosphate
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
Lgm Pharma

The sponsor is the company that holds the FDA application; it can differ from the labeler.

Recall timeline

2026

  1. June 4, 2026 · Class II · Ongoing · D-0583-2026 · Duloxetine

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

    Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by

  2. June 4, 2026 · Class II · Ongoing · D-0582-2026 · Duloxetine

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

    Duloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles, Rx only, Manufactured. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceuticals, Inc., Berke

  3. April 21, 2026 · Class II · Ongoing · D-0522-2026 · Duloxetine

    CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

    Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., Martorelles, (Barcelona), Spain, Dist. by. Breckenridge Pharmaceutical, Inc., Berkely Heights, NJ 07922, N

2025

  1. November 24, 2025 · Class II · Ongoing · D-0216-2026 · Duloxetine

    CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

    Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical Inc., Berkel

  2. October 9, 2025 · Class II · Ongoing · D-0100-2026 · Duloxetine

    CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.

    Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90), b.)1000-count bottle (NDC 51991-748-10),Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain; Dist.

  3. July 15, 2025 · Class II · Ongoing · D-0552-2025 · Duloxetine

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit

    Duloxetine Delayed-Release Capsules, USP, 60mg, 1,000-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceuticals, Inc., Berkeley Height

  4. June 30, 2025 · Class II · Ongoing · D-0511-2025 · Duloxetine

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

    Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 079

  5. April 14, 2025 · Class II · Ongoing · D-0388-2025 · Duloxetine

    CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

    Duloxetine Delayed-Release Capsules USP, 30 mg, a.) 90-count bottles (NDC# 51991-747-90), b.) 1000-count bottles (NDC 51991-747-10), Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L. Distributed by Breckenridge P

  6. April 14, 2025 · Class II · Ongoing · D-0387-2025 · Duloxetine

    CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

    Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L., Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922, NDC# 51991-748-1

  7. March 26, 2025 · Class II · Ongoing · D-0308-2025 · Duloxetine

    CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.

    Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per bottle, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical, Inc.,

Show the 11 older recalls

2025

  1. February 28, 2025 · Class II · Ongoing · D-0271-2025 · Duloxetine

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

    Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07

  2. February 28, 2025 · Class II · Ongoing · D-0269-2025 · Duloxetine

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

    Duloxetine Delayed-Release Capsules, USP, 60mg, Rx Only, 1000-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 0

  3. February 28, 2025 · Class II · Ongoing · D-0270-2025 · Duloxetine

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

    Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 1000-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 0

2024

  1. December 6, 2024 · Class II · Ongoing · D-0162-2025 · Duloxetine

    CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

    Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx Only, 90-count bottles (NDC 51991-748-90) Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berke

  2. December 6, 2024 · Class II · Ongoing · D-0161-2025 · Duloxetine

    CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

    Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 90-count bottles (NDC 51991-747-90) Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkel

  3. October 10, 2024 · Class II · Completed · D-0009-2025 · Duloxetine

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

    Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Distributed by: BPI, NDC 51991-746-05.

  4. May 17, 2024 · Class II · Terminated · D-0562-2024 · Duloxetine

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

    Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 0792

  5. April 29, 2024 · Class II · Ongoing · D-0484-2024 · Duloxetine

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

    Duloxetine Delayed-Release Capsules, USP, 60 mg, 90-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07

  6. April 29, 2024 · Class II · Ongoing · D-0482-2024 · Duloxetine

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

    Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, (a) 90-count bottles (NDC 51991-747-90), (b) 1000-count bottles (NDC 51991-747-10), Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist

  7. April 29, 2024 · Class II · Ongoing · D-0483-2024 · Duloxetine

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

    Duloxetine Delayed-Release Capsules, USP, 20 mg, , 500-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ

2015

  1. October 21, 2015 · Class III · Terminated · D-0181-2016 · Duloxetine

    Presence of Foreign Tablets/Capsules: one foreign capsule identified as omeprazole 10 mg was found in the bottle

    Duloxetine Delayed-release Capsules, USP, 60 mg, Rx Only, 1000 count bottle, Manufactured by: Laboratorios Dr. Esteve, S.A., Barcelona, Spain, Distributed by: Breckenridge Pharmaceutical, Inc., Boca Raton, FL 33487, NDC:

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026

FDA Enforcement Report search → · Report an error →